Rydapt® Too Expensive? Access Generic Equivalents (Midostaurin) Through Global Personal Import

Summary - Midostaurin is a targeted cancer therapy drug used in specific blood cancers, most commonly in FLT3-mutation–positive acute myeloid leukemia and certain advanced forms of systemic mastocytosis. The clinical indications are well established. What remains inconsistent across countries is how, and how quickly, patients can actually access the medicine once it has been prescribed. This article explains what Midostaurin does, who it is prescribed for, and why cost and availability create obstacles in many healthcare systems. It also explores how some patients are using legally compliant named-patient import pathways to obtain affordable generic Midostaurin through MedsPartner.

Midostaurin, sold under the brand name Rydapt®, is an oral cancer medicine used in specific treatment settings, usually in specialist or hospital-based care. Depending on the situation, it may be given alongside chemotherapy or continued as part of longer-term disease control. Its use is limited to a small group of rare blood cancers that affect the bone marrow and related tissues, most notably acute myeloid leukemia (AML) and systemic mastocytosis.

The medicine comes as oral capsules and is priced as a specialty oncology drug, which creates several practical issues when it comes to access. Insurance approvals can take weeks, coverage may be partial, and out-of-pocket costs, even with insurance, can be substantial. In many countries, access to Midostaurin is inconsistent even when public health programs exist, and in some regions, the medicine is not commercially available at all.

This unpredictability over costs and availability puts patients and caregivers in a difficult position, with the experience being quite common and not limited to any one healthcare system. This is where alternative access routes to safe and affordable generic equivalents come into the picture.

MedsPartner sources generic Midostaurin from facilities in India that meet international quality standards and makes it available globally through personal import pathways for patients with a valid prescription. Here’s how patients can access affordable Rydapt® through this method.

What is Midostaurin/Rydapt® prescribed for?

Midostaurin is a targeted cancer therapy used in very specific types of blood cancers.

In acute myeloid leukemia (AML), it is prescribed when testing confirms the presence of a FLT3 mutation. It is typically given in combination with chemotherapy at the early diagnosis stage - with some patients continuing treatment afterward. It is also approved for advanced systemic mastocytosis -  including aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL).

How does Midostaurin work - Mechanism of action

Midostaurin belongs to a class of kinase inhibitor drugs. These drugs interfere with internal signals that allow abnormal blood cells to grow and survive.

In FLT3-positive AML, the FLT3 gene mutation causes continuous signaling that promotes leukemia cell growth. Midostaurin reduces this activity by inhibiting the FLT3 kinase protein. In systemic mastocytosis, it also affects KIT - another kinase protein - and related pathways that contribute to the buildup of mast cells, which, over time, can damage organs.

Midostaurin - Recent News and Updates

Midostaurin has been prescribed for several years now. Recent research has examined ‘combination regimens’ and the extent of cancer remission, specifically MRD (measurable residual disease) negativity. Patients who clear more disease from their bone marrow tend to relapse less often.

A UK study published in December 2025 looked at 77 people with FLT3-mutated AML who were prescribed midostaurin along with intensive chemotherapy and gemtuzumab ozogamicin. The results were very encouraging. The response rate was found to be 91% and the two-year survival rate was 77%. .

For patients who also had an NPM1 mutation, adding midostaurin made a clear difference. 81% had no detectable cancer cells after the second round of treatment, compared to only 68% when midostaurin was not used.

Doctors are also working out how midostaurin fits with newer FLT3 inhibitors during consolidation and after remission. The focus right now is on sequencing - using these drugs in a particular order based on each patient's situation - not on replacing midostaurin completely.

How much does Midostaurin cost - before and after insurance?

Midostaurin pricing varies widely across countries and insurance plans. In the United States, the list price for branded Rydapt® starts around $11,928 for 56 capsules of 25mg. For a typical patient, the annual cost for AML treatment is approximately $195,405, and for advanced systemic mastocytosis, around $390,811. In the UK, the list price is £5,610 for a 56-pack of 25mg capsules, which works out to around £73,000 annually for continuous treatment at 100mg twice daily, as in the case of ASM and MCL.

Several factors drive these high prices. The drug treats rare diseases with small patient populations. Development and regulatory costs get spread across fewer patients. Patent protection further limits competition in most markets. Hospital-based procurement systems can reduce transparency around actual costs paid by health systems.

Even if you have insurance, midostaurin can still be expensive. Drug makers like Novartis offer co-pay assistance programs that may lower the cost to about $25 per prescription. But these programs usually have yearly limits. On top of that, paperwork like prior approvals, specialty pharmacy requirements, and insurance rules often slow things down - meaning patients can still face delays in starting treatment.

Are there generic versions of Rydapt® available? And how can I access them?

Generic versions of Rydapt® (midostaurin capsules) were approved by the FDA in 2024, with Lupin approved in May and Dr. Reddy’s Laboratories in June. These generics carry an AB rating, meaning they meet FDA bioequivalence standards, but active patents prevent them from being sold through U.S. pharmacies until at least 2028 for AML and 2030 for systemic mastocytosis.

Outside the U.S., generic Midostaurin, particularly from India, has been available for longer and at much lower cost. India’s role as a major producer of generic oncology medicines, combined with lower manufacturing costs and pricing controls, makes these versions more affordable while meeting international quality standards.

Through MedsPartner, generic Midostaurin (25mg, 28 capsules) is available for $540 USD, which works out to roughly $19 per capsule. The medicine is manufactured in FDA/EMA-approved facilities that meet international quality standards.

Here’s the cost comparison at a glance - 

• US list price (branded Rydapt®): ~$213 per 25mg capsule
• UK list price (branded Rydapt®): ~£100 per 25mg capsule
• MedsPartner (midostaurin generic): ~$19 per 25mg capsule - Offering >90% savings for most patients

Patients in many countries can import a limited supply of prescription medicines for personal use when local access is unavailable or unaffordable. 

MedsPartner specialises in this process and supports patients and families in need by verifying prescriptions, coordinating documentation, and arranging tracked international delivery within 1-2 weeks.

How can I order Midostaurin through MedsPartner?

1. Upload your doctor's Midostaurin prescription (that mentions dose, strength, duration) via MedsPartner’s product page.

2. Our team verifies the prescription validity and dosage, and your country's import limits. You can avail a free consultation on the process by writing to us at support@medspartner.com or by placing an order here.

3. We send you a quotation as per your order. You can pay online accordingly.

4. We source high-quality Midostaurin from trusted FDA/EMA-approved manufacturers. Each order is packed after strict quality checks.

5. We ship the meds through trusted logistics partners - with complete, customs-compliant documentation.

6. Our team shares real-time tracking details with you, so you can track your shipment end-to-end until it is delivered to your doorstep.

How MedsPartner helped with timely midostaurin treatment for a patient in Brazil

Samuel from Brazil was recently diagnosed with FLT3-positive acute myeloid leukemia and prescribed Midostaurin. When his family checked with local pharmacies, they were quoted exorbitant prices for the drug - beyond their means.

At that price, the cost of treatment was far beyond what the family could manage out of pocket. Though generic Midostaurin was advised by their oncologist, the family found it difficult to find it regularly in their local pharmacies. His insurance was about to lapse, too, and eligibility for the high specialty drug proved to be an issue during the transition phase.

While researching options online, Samuel’s brother came across MedsPartner and its compliant personal-import pathway for cancer medicines. After an initial discussion, the family uploaded Samuel’s prescription and received guidance on the documentation required for Brazil.

Once the documents were verified, the family placed an order for generic Midostaurin. Through MedsPartner, the cost for 25 mg capsules (28 capsules) was USD 540, or about USD 19 per capsule, translating to savings of more than 90% compared to the local price of branded Rydapt® in Brazil, yet at the same safety and efficacy.

The medicine was shipped with full customs-compliant documentation and tracking and arrived at their home within about ten days. “What helped us most was knowing the treatment could continue without interruption,” Samuel’s mother said. “The cost difference was significant, but just as important was the predictability of having the medicine arrive on time.”

这只是 3 万多个患者故事中的一个，这些故事展示了通过 MedsPartner 以安全、负担得起的方式获取药品是如何带来真正的改变。

Your FAQs on Midostaurin generics from MedsPartner - Answered

Q1. How much can I save by ordering Midostaurin through MedsPartner?

A - Savings are usually significant, >90% for most patients. In many countries, branded Rydapt® can cost well over USD 15,000 per month, while the generic Midostaurin supplied through MedsPartner is priced at USD 540 for 25 mg for the same quantity. 

Q2. How can I trust MedsPartner with a critical cancer medicine?

A - MedsPartner sources medicines from trusted manufacturers with FDA/EMA-approved facilities. Our licensed pharmacists verify every prescription, and we ship medicines in original, sealed packaging with full tracking. To date, MedsPartner has supported 30,000+ patients across 40+ countries and maintains a 4.4-star rating on Trustpilot.

Q3. Is importing Midostaurin for personal use legal?

A - In many countries, personal-use import of prescription medicines is permitted with a valid prescription and within allowed quantity limits. MedsPartner checks country-specific regulations and assists with compliant documentation before confirming any order.

Q4. What if my insurance has denied coverage, or my co-pay for Rydapt® is too high?

A- This is often the point at which patients reach out to MedsPartner. Accessing quality-assured generics through the personal import pathway can help maintain treatment continuity in cases of insurance denials and high co-pays.

Q5. I am a doctor. How can I help my patient access Midostaurin through MedsPartner?

A - Doctors can write directly to support@medspartner.com for guidance. MedsPartner verifies the prescription and provides a free consultation to the patient on the personal import process, followed by checking country-specific import rules. We support your patient with thorough documentation, tracking, and timely doorstep delivery of the medicine.

Q6. What are the side effects of Midostaurin?

A - Common side effects of Midostaurin include nausea, vomiting, diarrhea, fatigue, headache, elevated blood sugar, and low blood cell counts. Some patients also show increases in liver enzymes. Your doctor can help you track side effects and manage dosage accordingly.

Q7. Are there ways to reduce the cost of midostaurin if assistance programs don’t work?

A - Yes. Manufacturer co-pay programs can lower costs for some patients, but they have limits, strict eligibility rules, and can still cause delays. When these programs fall short, personal import of generic midostaurin through MedsPartner is a viable option, allowing patients to access quality-assured treatment at a lower cost with a valid prescription.

Need help accessing affordable Midostaurin?

If Midostaurin has been prescribed to you or your loved one, but the price is unaffordable, insurance is taking time, or the medicine isn’t reliably available where you live, you’re not alone. Many patients and caregivers encounter these difficulties during their AML, ASM, or MCL treatments.

MedsPartner helps patients and families navigate this gap by supporting access to quality-assured generic Midostaurin through compliant personal-import pathways. With prescription checks, documentation support, and tracked delivery handled end to end, families can focus less on logistics and more on staying on treatment.

Contact us for a free consultation and assistance with personal import of rucaparib, or place an order on our website.

About the Author - Aayyush Goyal has a background in healthcare consulting and pharmaceutical supply chains, with over a decade of experience in drug pricing, regulatory policy, and patient rights. He has advised patients, advocacy groups, and healthcare providers across 40+ countries on safe and compliant access to essential medicines. Through MedsPartner, Aayyush has overseen more than 30,000 successful patient deliveries worldwide, ensuring affordability without compromising safety or legality. He is a recognized advocate for ethical sourcing, generic access, and cross-border care solutions, and has contributed insights on global drug access in healthcare forums, media publications, and patient support networks.